NeuroSearch A/S
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NeuroSearch A/S
Levicept Looks For No Pain, More Gain With Osteoarthritis Offering
The UK firm is weighing up its options for late-stage development of LEVI-04 after unveiling positive Phase II results of Phase II for the neurotrophin-3 inhibitor in moderate-to-severe osteoarthritis.
Deal Watch: BI Acquires Nerio For Novel Immune Checkpoint Inhibitor
Featuring deals involving Novartis/Dren, Palvella/Pieris, Eyenovia/Senju, Addex/Johnson & Johnson, Agilent/BioVectra, Meitheal/Nabriva, plus tech transfer agreements and deals in brief.
Rare Diseases Rule, But Some Common Conditions Stand Out In Pending US Applications
Half of the FDA’s upcoming 2024 user fee goals target rare diseases, but highly prevalent conditions like uncomplicated urinary tract infections and atopic dermatitis are also up for agency action in the second half of the year.
Chinese Biotech Funding Rebounds As $100m VC/PE Deals Return
AI specialist METiS Pharmaceuticals raked in $100m in a series C round, while four other deals backed by venture capital and private equity firms crossed the CNY100m ($14m) mark in the latest fundraisings by Chinese biopharma companies.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice